Patents by Inventor Satheesh Balasubramanian

Satheesh Balasubramanian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12233049
    Abstract: The present invention relates to liquid pharmaceutical compositions of clonidine or its pharmaceutically acceptable salts thereof. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and are stable for extended periods of time. More specifically, stable liquid pharmaceutical compositions of clonidine at concentrations of 1 ?g/mL or more are provided. The present invention further relates to stable oral liquid compositions of clonidine, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by clonidine.
    Type: Grant
    Filed: July 15, 2022
    Date of Patent: February 25, 2025
    Assignee: SLAYBACK PHARMA LLC
    Inventors: Shailendra Mandge, Harish Gunda, Naga Venkata Durga Prasad Ketha, Venkateshwar Reddy Keesara, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai
  • Publication number: 20250049824
    Abstract: The present invention relates to stable liquid oral compositions of cyclophosphamide having extended stability, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cyclophosphamide. The invention also relates to a kit comprising stable liquid oral compositions of cyclophosphamide.
    Type: Application
    Filed: October 24, 2024
    Publication date: February 13, 2025
    Applicant: SLAYBACK PHARMA LLC
    Inventors: Shailendra MANDGE, Harish GUNDA, Naga Venkata Durga Prasad KETHA, Venkateshwar Reddy KEESARA, Satheesh Balasubramanian, Sumitra Ashokkumar PILLAI
  • Patent number: 12213972
    Abstract: The present invention relates to stable pharmaceutical compositions comprising apixaban or its pharmaceutically acceptable salts thereof. The present invention further relates to a capsule composition comprising a therapeutically effective amount of apixaban solubilized or dispersed in a pharmaceutically acceptable carrier, wherein the therapeutically effective amount of apixaban ranges from about 0.5 mg/unit dosage form to about 50 mg/unit dosage form. The present invention also provides manufacturing processes thereof and use of the said compositions for prevention, treatment or prophylaxis of disorders in human patients in need thereof.
    Type: Grant
    Filed: January 23, 2024
    Date of Patent: February 4, 2025
    Assignee: SLAYBACK PHARMA LLC
    Inventors: Shailendra Mandge, Venkateshwar Reddy Keesara, Harish Gunda, Naga Venkata Durga Prasad Ketha, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai, Sushant Omprakash Dube, Praveen Kumar Subbappa
  • Publication number: 20250032586
    Abstract: Stable injectable compositions comprising glucagon or a pharmaceutically acceptable salt, solvate, or hydrate thereof are disclosed, which comprise (a) a therapeutically effective amount of glucagon; (b) at least one pharmaceutically acceptable solvent; (c) at least one stabilizing agent; (d) at least one sugar; and (e) optionally, at least one pharmaceutically acceptable excipient; wherein said injectable solution is stable and ready-to-use, and wherein pH of the said solution ranges from 3.8 to 4.2. Preferably, the composition is provided in a sealed container, e.g., an ampoule, a vial, a pre-filled syringe or an auto-injector. Further, stable injectable solutions are disclosed, which comprise glucagon or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and which are suitable for subcutaneous, intravenous or intramuscular administration. Methods for manufacturing stable injectable solutions of glucagon are also disclosed.
    Type: Application
    Filed: September 25, 2024
    Publication date: January 30, 2025
    Applicant: Slayback Pharma LLC
    Inventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Lourdu Chinnu Thippabattuni, . Satheesh Balasubramanian, Sumitra Ashokkumar Pillai, Praveen Kumar Subbappa
  • Patent number: 12208086
    Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.
    Type: Grant
    Filed: November 6, 2023
    Date of Patent: January 28, 2025
    Assignee: SLAYBACK PHARMA LLC
    Inventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Sumitra Ashokkumar Pillai, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian
  • Patent number: 12128089
    Abstract: Stable injectable compositions comprising glucagon or a pharmaceutically acceptable salt, solvate, or hydrate thereof are disclosed, which comprise (a) a therapeutically effective amount of glucagon; (b) at least one pharmaceutically acceptable solvent; (c) at least one stabilizing agent; (d) at least one sugar; and (e) optionally, at least one pharmaceutically acceptable excipient; wherein said injectable solution is stable and ready-to-use, and wherein pH of the said solution ranges from 3.8 to 4.2. Preferably, the composition is provided in a sealed container, e.g., an ampoule, a vial, a pre-filled syringe or an auto-injector. Further, stable injectable solutions are disclosed, which comprise glucagon or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and which are suitable for subcutaneous, intravenous or intramuscular administration. Methods for manufacturing stable injectable solutions of glucagon are also disclosed.
    Type: Grant
    Filed: May 25, 2023
    Date of Patent: October 29, 2024
    Assignee: SLAYBACK PHARMA LLC
    Inventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai, Praveen Kumar Subbappa
  • Publication number: 20240350459
    Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.
    Type: Application
    Filed: June 28, 2024
    Publication date: October 24, 2024
    Applicant: SLAYBACK PHARMA LLC
    Inventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Sumitra Ashokkumar Pillai, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian
  • Publication number: 20240285582
    Abstract: The present invention relates to liquid pharmaceutical compositions of edaravone. More specifically, stable solutions of edaravone for enteral administration are provided, wherein the composition is stable for extended period of time. The present invention further relates to stable solutions of edaravone, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by edaravone.
    Type: Application
    Filed: June 23, 2023
    Publication date: August 29, 2024
    Applicant: Slayback Pharma LLC
    Inventors: Sushant Omprakash Dube, Girish G. Kore, Abhijit Balaji Pawar, Jagdish Lotan Lohar, Praveen Kumar Subbappa, Sumitra Ashokkumar Pillai, Parvateesam Yenda, Satheesh Balasubramanian
  • Patent number: 12059406
    Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.
    Type: Grant
    Filed: November 6, 2023
    Date of Patent: August 13, 2024
    Assignee: SLAYBACK PHARMA LLC
    Inventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Sumitra Ashokkumar Pillai, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian
  • Publication number: 20240197705
    Abstract: The present invention relates to stable pharmaceutical compositions comprising apixaban or its pharmaceutically acceptable salts thereof. The present invention further relates to a capsule composition comprising a therapeutically effective amount of apixaban solubilized or dispersed in a pharmaceutically acceptable carrier, wherein the therapeutically effective amount of apixaban ranges from about 0.5 mg/unit dosage form to about 50 mg/unit dosage form. The present invention also provides manufacturing processes thereof and use of the said compositions for prevention, treatment or prophylaxis of disorders in human patients in need thereof.
    Type: Application
    Filed: January 23, 2024
    Publication date: June 20, 2024
    Applicant: Slayback Pharma LLC
    Inventors: Shailendra Mandge, Venkateshwar Reddy Keesara, Harish Gunda, Naga Venkata Durga Prasad Ketha, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai, Sushant Omprakash Dube, Praveen Kumar Subbappa
  • Publication number: 20240180934
    Abstract: The present invention relates to stable liquid oral compositions of cyclophosphamide having extended stability, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cyclophosphamide. The invention also relates to a kit comprising stable liquid oral compositions of cyclophosphamide.
    Type: Application
    Filed: February 14, 2024
    Publication date: June 6, 2024
    Applicant: SLAYBACK PHARMA LLC
    Inventors: Shailendra MANDGE, Harish Gunda, Naga Venkata Durga Prasad Ketha, Venkateshwar Reddy Keesara, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai
  • Publication number: 20240156829
    Abstract: The present invention relates to stable pharmaceutical compositions for parenteral administration comprising aprepitant. The present invention further relates to a method for manufacturing the composition as well as to the use of these compositions. Also included are stable pharmaceutical compositions for parenteral administration comprising aprepitant and palonosetron. The pharmaceutical compositions are stable oil-in-water emulsions for parenteral administration and are particularly useful for the prevention and control of acute and delayed chemotherapy-induced nausea and vomiting (CINV), for the prevention of postoperative nausea and vomiting (PONV), and/or for the prevention of radiation induced nausea and vomiting (RINV).
    Type: Application
    Filed: October 16, 2023
    Publication date: May 16, 2024
    Inventors: Ashish Anilrao Dubewar, Rahul Dhutaji Bhise, Shanker Mamidi, Mahadeo Vasant Mahadik, Sumitra Ashokkumar Pillai, Satheesh Balasubramanian, Kumar Swamy Ummiti, Mayur Anshiram Adhav, Praveen Kumar Subbappa
  • Patent number: 11931370
    Abstract: The present invention relates to stable liquid oral compositions of cyclophosphamide having extended stability, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cyclophosphamide. The invention also relates to a kit comprising stable liquid oral compositions of cyclophosphamide.
    Type: Grant
    Filed: October 7, 2022
    Date of Patent: March 19, 2024
    Assignee: SLAYBACK PHARMA LLC
    Inventors: Shailendra Mandge, Harish Gunda, Naga Venkata Durga Prasad Ketha, Venkateshwar Reddy Keesara, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai
  • Publication number: 20240075014
    Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.
    Type: Application
    Filed: November 6, 2023
    Publication date: March 7, 2024
    Applicant: SLAYBACK PHARMA LLC
    Inventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Sumitra Ashokkumar Pillai, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian
  • Publication number: 20240050416
    Abstract: The present invention relates to stable pharmaceutical compositions comprising apixaban or its pharmaceutically acceptable salts thereof. The present invention further relates to a capsule composition comprising a therapeutically effective amount of apixaban solubilized or dispersed in a pharmaceutically acceptable carrier, wherein the therapeutically effective amount of apixaban ranges from about 0.5 mg/unit dosage form to about 50 mg/unit dosage form. The present invention also provides manufacturing processes thereof and use of the said compositions for prevention, treatment or prophylaxis of disorders in human patients in need thereof.
    Type: Application
    Filed: July 24, 2023
    Publication date: February 15, 2024
    Applicant: Slayback Pharma LLC
    Inventors: Shailendra Mandge, Venkateshwar Reddy Keesara, Harish Gunda, Naga Venkata Durga Prasad Ketha, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai, Sushant Omprakash Dube, Praveen Kumar Subbappa
  • Patent number: 11844784
    Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.
    Type: Grant
    Filed: June 2, 2023
    Date of Patent: December 19, 2023
    Assignee: SLAYBACK PHARMA LLC
    Inventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Sumitra Ashokkumar Pillai, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian
  • Publication number: 20230381282
    Abstract: Stable injectable compositions comprising glucagon or a pharmaceutically acceptable salt, solvate, or hydrate thereof are disclosed. Preferably, the composition is provided in a sealed container, e.g., an ampoule, a vial, a pre-filled syringe or an auto-injector. Further, stable injectable solutions are disclosed, which comprise glucagon or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and which are suitable for subcutaneous, intravenous or intramuscular administration. Methods for manufacturing stable injectable solutions of glucagon are also disclosed.
    Type: Application
    Filed: May 25, 2023
    Publication date: November 30, 2023
    Applicant: Slayback Pharma LLC
    Inventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai, Praveen Kumar Subbappa
  • Publication number: 20230310384
    Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.
    Type: Application
    Filed: June 2, 2023
    Publication date: October 5, 2023
    Applicant: SLAYBACK PHARMA LLC
    Inventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Sumitra Ashokkumar Pillai, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian
  • Publication number: 20230301945
    Abstract: The present invention relates to stable oral pharmaceutical compositions in the form of a solution comprising: hydroxyurea at a concentration of about 10 mg/mL to about 500 mg/mL; at least one pharmaceutically acceptable liquid vehicle; and one or more amino acids selected from the group consisting of glycine, alanine, glutamic acid, L-arginine, lysine, L-cysteine, methionine and mixtures thereof, wherein the level of carbamoyloxyurea in the solution is less than 0.5 % w/w as measured by HPLC when the solution is stored at 25° C./60% RH for at least 3 months. The invention further relates to processes for the production of the compositions, methods for their administration, and their use for treatment of diseases treatable by hydroxyurea.
    Type: Application
    Filed: February 2, 2023
    Publication date: September 28, 2023
    Applicant: Slayback Pharma LLC
    Inventors: Shailendra Mandge, Venkateshwar Reddy Keesara, Harish Gunda, Naga Venkata Durga Prasad Ketha, Satheesh Balasubramanian ., Sumitra Ashokkumar Pillai, Praveen Kumar Subbappa
  • Patent number: 11707450
    Abstract: Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine or its pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: July 25, 2023
    Assignee: SLAYBACK PHARMA LLC
    Inventors: Harish Govindaraja Setty Chinnari, Somashekhar Battini, Sumitra Ashokkumar Pillai, Lourdu Chinnu Thippabattuni, Satheesh Balasubramanian